NCT00774332Unknown2 期
A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
Cooperative Study Group A for Hematology2 个研究点 分布在 2 个国家目标入组 37 人开始时间: 2006年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 37
- 试验地点
- 2
- 主要终点
- Duration of complete remission, disease-free survival, overall survival, toxicities
研究概览
简要总结
A Phase II Study of CODOX-M/ IVAC in Relapsed/Refractory ALL
详细描述
The feasibility will be evaluated in terms of complete remission rate, duration of complete remission, disease-free survival, overall survival, and toxicities.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 15 Years 至 65 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with relapsed/resistant acute lymphoblastic leukemia
- •Patients must be between 15 and 65 years of age.
- •Estimated life expectancy of more than 3 months
- •ECOG performance status of 2 or lower, Karnofsky scale > 60 (see appendix I)
- •Adequate cardiac function (EF>45%) on echocardiogram or MUGA scan
- •Adequate kidney function (estimated Ccr >50 ml/min)
排除标准
- •Patients with CNS involvement of leukemic blasts will not be excluded.
- •Patients with extramedullary relapse(s) only will be excluded.
结局指标
主要结局
Duration of complete remission, disease-free survival, overall survival, toxicities
时间窗: 2009
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)Multiple MyelomaNCT00091624Celgene Corporation77
已完成
2 期
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved DoseRelapse-Remitting Multiple SclerosisNCT00202982Teva Branded Pharmaceutical Products R&D, Inc.90
已完成
2 期
Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid LeukemiaAcute DiseaseNonlymphocytic LeukemiaMyelodysplastic SyndromesLeukemiaAcute Myeloid LeukemiaNCT00607997Sunesis Pharmaceuticals113
已完成
2 期
IFM2009-02-Pomalidomide and Dexamethasone Phase 2 MyelomaMultiple MyelomaNCT01053949University Hospital, Lille84
招募中
2 期
An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian CancerRecurrent Ovarian CancerNCT06560112Akeso172